scPharmaceuticals Future Growth
Future criteria checks 5/6
scPharmaceuticals is forecast to grow earnings and revenue by 66.3% and 45.3% per annum respectively while EPS is expected to grow by 67.5% per annum.
Key information
66.3%
Earnings growth rate
67.5%
EPS growth rate
| Pharmaceuticals earnings growth | 23.5% |
| Revenue growth rate | 45.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?
Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable
Jun 27The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts
Mar 16Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?
Nov 25scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients
Oct 20FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure
Oct 10Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?
Jan 11Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?
Sep 02scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX
Aug 26Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like
Mar 09How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?
Nov 24
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 186 | 28 | 40 | N/A | 5 |
| 12/31/2025 | 97 | -37 | -27 | -35 | 6 |
| 12/31/2024 | 39 | -61 | -61 | -68 | 6 |
| 6/30/2024 | 24 | -61 | -67 | -67 | N/A |
| 3/31/2024 | 18 | -58 | -60 | -60 | N/A |
| 12/31/2023 | 14 | -55 | -59 | -59 | N/A |
| 9/30/2023 | 7 | -50 | -56 | -56 | N/A |
| 6/30/2023 | 4 | -45 | -51 | -51 | N/A |
| 3/31/2023 | 2 | -40 | -44 | -44 | N/A |
| 12/31/2022 | N/A | -37 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -35 | -30 | -30 | N/A |
| 6/30/2022 | N/A | -31 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -29 | -26 | -26 | N/A |
| 12/31/2021 | N/A | -28 | -27 | -27 | N/A |
| 9/30/2021 | N/A | -28 | -29 | -29 | N/A |
| 6/30/2021 | N/A | -31 | -29 | -29 | N/A |
| 3/31/2021 | N/A | -32 | -29 | -29 | N/A |
| 12/31/2020 | N/A | -32 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -35 | -33 | -33 | N/A |
| 6/30/2020 | N/A | -32 | -34 | -34 | N/A |
| 3/31/2020 | N/A | -31 | -32 | -32 | N/A |
| 12/31/2019 | N/A | -33 | -30 | -30 | N/A |
| 9/30/2019 | N/A | -27 | -21 | -21 | N/A |
| 6/30/2019 | N/A | -27 | -21 | -21 | N/A |
| 3/31/2019 | N/A | -29 | -26 | -26 | N/A |
| 12/31/2018 | N/A | -29 | -29 | -29 | N/A |
| 9/30/2018 | N/A | -31 | -29 | -29 | N/A |
| 6/30/2018 | N/A | -31 | -30 | -29 | N/A |
| 3/31/2018 | N/A | -28 | N/A | -27 | N/A |
| 12/31/2017 | N/A | -24 | N/A | -23 | N/A |
| 9/30/2017 | N/A | -22 | N/A | -22 | N/A |
| 6/30/2017 | N/A | -26 | N/A | -20 | N/A |
| 3/31/2017 | N/A | -24 | N/A | -17 | N/A |
| 12/31/2016 | N/A | -24 | N/A | -15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SCPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: SCPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SCPH is expected to become profitable in the next 3 years.
Revenue vs Market: SCPH's revenue (45.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: SCPH's revenue (45.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SCPH's Return on Equity is forecast to be high in 3 years time